Novartis' bid for Excellergy cleared in Australia
( June 4, 2026, 05:28 GMT | Official Statement) -- MLex Summary: Switzerland-based Novartis Finance Corporation’s proposal to wholly acquire Excellergy, a US company, has been cleared by Australia's competition watchdog. The Australian Competition & Consumer Commission on Thursday said the acquisition is unlikely to substantially lessen competition, noting that any overlap is limited to early‑stage research and development of therapies for chronic spontaneous urticaria and food allergies, where competitive dynamics remain uncertain. The parties’ pipeline products are at an early and differentiated stage and other competitors will continue to constrain Novartis post‑acquisition, the watchdog said.Statement follows. Determination attached. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.